AUTHORS
Xueqing Dou, Yucheng Jiang2, Depei Wu Sr, MD3, Suning Chen4
AFFILIATIONS
1 The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases, Suzhou, China., Suzhou, China
2 The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases, Suzhou, China., Suzhou, China
3 The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases, Suzhou, China., Suzhou, China
4 The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases, Suzhou, China., Suzhou, China
ABSTRACT
Background
Acute myeloid leukemia (AML) harboring NPM1 mutations with wild-type FLT3-ITD is associated with favorable prognosis and high sensitivity to venetoclax-based therapy. However, whether venetoclax plus hypomethylating agents plus (VEN+HMA) can completely replace intensive chemotherapy and establish a chemo-free treatment paradigm for NPM1-mutated AML remains to be determined.
Aims
To evaluate the efficacy and safety of upfront VEN+HMA as a non-intensive, chemo-free regimen and to determine whether it can serve as an effective alternative to standard intensive chemotherapy in patients with newly diagnosed favorable-risk NPM1-mutated AML.
Methods
This prospective, multicenter, single-arm study enrolled patients aged ≥18 years with newly diagnosed NPM1-mutated AML and wild-type FLT3-ITD, classified as favorable-risk per the European LeukemiaNet (ELN) 2022 criteria. Patients received venetoclax (VEN) 400 mg orally once daily on days 1–28 (with a 3-day dose ramp-up in cycle 1 only) plus either azacitidine 75 mg/m² subcutaneously on days 1–7 or decitabine 20 mg/m² intravenously on days 1–5, in 28-day cycles. A total of 11 cycles were scheduled, followed by an observation phase. Primary endpoints were time to molecular minimal residual disease (MRD) negativity, defined as undetectable NPM1 by quantitative real-time PCR (qPCR), and time to molecular relapse, defined as confirmed ≥1-log increase in NPM1 transcripts from nadir or reappearance of detectable transcripts after prior negativity. Secondary endpoints included overall response rate (ORR), cumulative incidence of relapse (CIR), overall survival (OS), and safety (graded per CTCAE Version 5.0).
Results
Between June 2022 and June 2026, 40 patients were enrolled from 4 centers in China, with a median follow-up of 13.1 months (range 1.0–48.5). Median age was 55 years (range 15–80); 18 patients (45%) were male and 22 (55%) were female. NPM1 mutation subtypes included type A in 29 patients (72.5%), type B in 4 (10.0%), and other variants in 7 (17.5%). The median number of treatment cycles administered was 5.5 (range 1–14). Among the 39 patients evaluable for response to induction therapy (one died of sepsis during induction), the ORR after cycle 1 was 100% (39/39), with 35 patients achieving complete remission (CR) or complete remission with incomplete hematologic recovery (CRi) and 4 achieving complete remission with partial hematologic recovery (CRh). MRD monitoring was available in 36 of the 40 enrolled patients; among these 36 patients, 26 (72.2%) achieved molecular negativity, with a median of 2 cycles (range 1–8) to MRD negativity, corresponding to a median time of 3.3 months (range 1.2–15.9). Among the 26 patients who achieved MRD negativity, 4 (15.4%) subsequently relapsed molecularly at a median of 14.8 months (range 3.2–15.6) after MRD negativity. Molecular relapse occurred in 8 patients (8/36, 22.2%), 2 of whom subsequently progressed to hematologic relapse. The 2-year CIR of molecular relapse was 38.1%, and the 2-year CIR of hematologic relapse was 13.0%. Two patients died of sepsis (one during cycle 1 and one during cycle 2), yielding a 2-year OS rate of 95.0%.
Conclusions
Frontline VEN+HMA as a non-intensive regimen induces early and deep molecular remissions in low-risk NPM1-AML. However, over one-third of patients experienced molecular relapse within 2 years, underscoring the need for larger studies with extended follow-up to definitively assess long-term outcomes.
DISCLOSURES
Xueqing Dou: No relevant conflicts of interest to declare.